USE OF LISURIDE IN ADVANCED PARKINSONS-DISEASE - POTENT DOPAMINE AND SEROTONIN AGONIST

被引:0
|
作者
LIEBERMAN, AN [1 ]
GOLDSTEIN, M [1 ]
NEOPHYTIDES, A [1 ]
LEIBOWITZ, M [1 ]
GOPINATHAN, G [1 ]
GOODGOLD, A [1 ]
PACT, V [1 ]
WALKER, R [1 ]
机构
[1] NYU, SCH MED, NEW YORK, NY 10003 USA
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:1751 / 1755
页数:5
相关论文
共 50 条
  • [31] TREATMENT OF PARKINSONS-DISEASE WITH THE PARTIAL DOPAMINE AGONIST EMD 49980
    BRAVI, D
    DAVIS, TL
    MOURADIAN, MM
    CHASE, TN
    MOVEMENT DISORDERS, 1993, 8 (02) : 195 - 197
  • [32] EARLY COMBINATION OF DOPAMINE AGONIST AND LEVODOPA IN THE TREATMENT OF PARKINSONS-DISEASE
    RINNE, UK
    MOUNT SINAI JOURNAL OF MEDICINE, 1988, 55 (02): : 138 - 141
  • [33] THE RATIONALE FOR THE USE OF DOPAMINE AGONISTS IN PARKINSONS-DISEASE
    JENNER, P
    NEUROLOGY, 1995, 45 (03) : 6 - 12
  • [35] REDUCTION OF CORTICAL DOPAMINE, NORADRENALINE, SEROTONIN AND THEIR METABOLITES IN PARKINSONS-DISEASE
    SCATTON, B
    JAVOYAGID, F
    ROUQUIER, L
    DUBOIS, B
    AGID, Y
    BRAIN RESEARCH, 1983, 275 (02) : 321 - 328
  • [36] A NEW APPROACH TO THE USE OF DOPAMINE AGONIST IN THE TREATMENT OF PARKINSONS-DISEASE - EARLY COMBINATION WITH LEVODOPA
    RINNE, UK
    ACTA PHYSIOLOGICA ET PHARMACOLOGICA LATINOAMERICANA, 1987, 37 (01): : 190 - 190
  • [37] THERAPEUTIC EXPERIENCE WITH THE NEW DOPAMINE AGONIST CU-32-085 IN ADVANCED PARKINSONS-DISEASE
    BIESEMEYER, H
    LUDIN, HP
    RINGWALD, E
    JOURNAL OF NEUROLOGY, 1983, 230 (01) : 19 - 23
  • [38] SEROTONIN AND PARKINSONS-DISEASE - REPLY
    CUMMINGS, JL
    AMERICAN JOURNAL OF PSYCHIATRY, 1993, 150 (05): : 844 - 844
  • [39] LISURIDE PLUS SELEGILINE IN THE TREATMENT OF EARLY PARKINSONS-DISEASE
    NAPPI, G
    MARTIGNONI, E
    HOROWSKI, R
    PACCHETTI, C
    RAINER, E
    BRUGGI, P
    RUNGE, I
    ACTA NEUROLOGICA SCANDINAVICA, 1991, 83 (06): : 407 - 410
  • [40] MK-458, A SELECTIVE AND POTENT D2 RECEPTOR AGONIST IN ADVANCED PARKINSONS-DISEASE
    LIEBERMAN, A
    CHIN, L
    BAUMANN, G
    CLINICAL NEUROPHARMACOLOGY, 1988, 11 (03) : 191 - 200